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Abstract
Background: This study evaluated the relation between adiponectin and atherosclerosis in both genders, and investigated
whether adiponectin provides useful additional information for assessing the risk of atherosclerosis.
Methods: We measured serum adiponectin levels and other cardiovascular risk factors in 1033 subjects (454 men, 579
women) from the Korean Genomic Rural Cohort study. Carotid intima–media-thickness (CIMT) was used as measure of
atherosclerosis. Odds ratios (ORs) with 95% confidence intervals (95% CI) were calculated using multiple logistic regression,
and receiver operating characteristic curves (ROC), the category-free net reclassification improvement (NRI) and integrated
discrimination improvement (IDI) were calculated.
Results: After adjustment for conventional cardiovascular risk factors, such as age, waist circumference, smoking history,
low-density and high-density lipoprotein cholesterol, triglycerides, systolic blood pressure and insulin resistance, the ORs
(95%CI) of the third tertile adiponectin group were 0.42 (0.25–0.72) in men and 0.47 (0.29–0.75) in women. The area under
the curve (AUC) on the ROC analysis increased significantly by 0.025 in men and 0.022 in women when adiponectin was
added to the logistic model of conventional cardiovascular risk factors (AUC in men: 0.655 to 0.680, p = 0.038; AUC in
women: 0.654 to 0.676, p = 0.041). The NRI was 0.32 (95%CI: 0.13–0.50, p,0.001), and the IDI was 0.03 (95%CI: 0.01–0.04,
p,0.001) for men. For women, the category-free NRI was 0.18 (95%CI: 0.02–0.34, p = 0.031) and the IDI was 0.003 (95%CI:
20.002–0.008, p = 0.189).
Conclusion: Adiponectin and atherosclerosis were significantly related in both genders, and these relationships were
independent of conventional cardiovascular risk factors. Furthermore, adiponectin provided additional information to
conventional cardiovascular risk factors regarding the risk of atherosclerosis.
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Introduction
Adipose tissue, beyond the concept of functioning as a passive
energy reservoir, has been studied as an active endocrine organ
linked to atherosclerosis [1]. Adipose tissue synthesizes and
secretes various adipokines, such as adiponectin and leptin [2].
Adiponectin is likely to play a protective role against atheroscle-
rosis and cardiovascular risk [3]. The expression of adiponectin is
inversely correlated with obesity, insulin resistance [4], and
development of early atherosclerosis [5]. Because adiponectin
exerts protective effects on the cardiovascular system, it could also
be highlighted as a therapeutic target molecule for preventing
atherosclerosis and atherosclerotic events [6]. Furthermore, we
have previously reported that adiponectin has an inverse
correlation with carotid intima–media thickness in Korean
subjects, after adjustment for gender [7].
However, some studies reported that adiponectin was a useful
marker of atherosclerosis in men, but not in women [8].
Furthermore, the Framingham Offspring Study also revealed that
adiponectin is an independent risk factor for coronary heart
disease in men, but this association was attenuated and lost its
significance in women after adjustment for conventional risk
factors for cardiovascular diseases, including obesity parameters
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[9]. The MONICA/KORA Augsburg study indicated that
adiponectin is insufficient for predicting the prognosis of athero-
sclerosis after adjustment for conventional cardiovascular risk
factors [10]. However, it is unknown whether these results were
indicative of the exact relation between adiponectin and athero-
sclerosis in each gender because the MONICA/KORA Augsburg
study did not use stratified analyses according to gender.
Therefore, we undertook this investigation to elucidate the role
of adiponectin for each gender separately.
Even though there is evidence to suggest an independent anti-
atherosclerotic role for adiponectin [11], it remains unclear
whether adiponectin is independently associated with atheroscle-
rosis after controlling for conventional cardiovascular risk factors,
such as blood pressure, lipid profile, insulin resistance, and waist
circumference in each gender. Even if adiponectin levels are
associated with atherosclerosis, independently of other cardiovas-
cular risk factors, it is still uncertain whether adiponectin can make
an additional contribution to predicting the risk of atherosclerosis,
as an adjunct to conventional cardiovascular risk factors.
The aims of this study were: 1) to elucidate the relation of
adiponectin to atherosclerosis for each gender specifically in
gender-stratified analyses; 2) to determine whether adiponectin is
independent of other cardiovascular risk factors; 3) to evaluate
whether adiponectin provides additional information regarding
the risk of atherosclerosis, beyond that provided by conventional
cardiovascular risk factors.
Methods
Study Population
The Korean Genomic Rural Cohort (KGRC) study is a part of
the Korean Genome and Epidemiology Study (KoGES), an
ongoing multicenter cohort study to assess the prevalence,
incidence and risk factors for chronic degenerative disorders such
as hypertension, diabetes, osteoporosis, and cardiovascular disease
[12]. The KoGES study currently comprises a general adult
population in 5 geographic areas from November 2005 to March
2011. Within this cohort, data for both serum adiponectin levels
and ultrasound images of the carotid artery were available from
1368 participants aged 45–75. Because adiponectin levels can be
affected by pharmacological medications, such as peroxisome
proliferator-activated receptor (PPAR)-gamma agonists [13], we
excluded 335 participants who were currently being treated with
pharmacological medications for diabetes, hypertension, or
dyslipidemia, as well as those who were under treatment for
cancer, based on self-reported questionnaires. Finally, a total of
1033 subject were included in the statistical analyses.
All participants provided written informed consent to their
participation, and the study was approved by the Institutional
Review Board of Wonju Christian Hospital.
Measurement of Anthropometric and Metabolic
Characteristics
Comprehensive questionnaires were used to collect medical
history. Physical examinations were carried out according to
standard procedures [14]. Body weight, height, and waist
circumference were measured while participants wore light indoor
clothing without shoes. Systolic blood pressure (SBP) and diastolic
blood pressure (DBP) were measured twice in the right arm using a
standard mercury sphygmomanometer (Baumanometer, USA).
The lower of the 2 observations of SBP and DBP was used in the
current study.
Venous blood samples were drawn from participants in the
morning, after they had fasted for 8 hours. Serum concentrations
of adiponectin were measured by radioimmunoassay (RIA)
Table 1. Anthropometric and metabolic characteristics of study population.
Men (n=454) Women (n=579) P value
Age, y 57.1767.16 55.4067.29 ,.001
Waist circumference, cm 87.1067.26 82.9268.63 ,.001
Body mass index 24.7363.73 24.3863.46 0.066
Smoking history, n (%) ,.001
current smoker 169 (37.22) 20 (4.41)
ex-smoker 137 (30.18) 4 (0.88)
non-smoker 148 (32.60) 555 (122.25)
SBP, mmHg 128.57615.86 130.03616.32 0.178
DBP, mmHg 82.95610.99 81.53610.50 0.017
FBG, mg/dL 95.25618.30 91.12616.43 ,.001
FBI, mIU/mL 6.90 (5.53–8.80) 7.80 (6.35–10.00) ,.001
HOMA-IR 1.60 (1.24–2.10) 1.74 (1.34–2.26) 0.003
Total cholesterol, mg/dL 201.43636.98 211.28640.28 ,.001
Triglycerides, mg/dL 134.50 (95.00–201.00) 118.00 (85.50–169.50) ,.001
HDL-C, mg/dL 46.00 (39.00–54.00) 47.00 (41.00–55.00) 0.005
LDL-C, mg/dL 116.40631.03 124.84633.99 ,.001
Adiponectin, mg/L 7.82 (5.63–11.05) 11.53 (8.41–14.86) ,.001
CIMT, mm 0.85 (0.72–1.00) 0.84 (0.72–0.96) 0.056
% of high CIMT (.0.9 mm), n (%) 197 (43.39) 227 (39.21) 0.196
SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose; FBI, fasting blood insulin;, HOMA-IR, Homeostasis model assessment-insulin
resistance; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; CIMT, carotid intima media thickness.
doi:10.1371/journal.pone.0075535.t001
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(LINCO Research, Inc., St Charles, MO, USA). Fasting blood
glucose (FBG) and insulin (FBI) were determined by a glucose
oxidize-based assay and double-antibody RIA. Serum concentra-
tions of low-density lipoprotein cholesterol (LDL-C), high-density
lipoprotein cholesterol (HDL-C), and triglycerides were deter-
mined by enzymatic methods (ADVIA 1650, Bayer, USA). Insulin
resistance was calculated using a homeostasis model (HOMA-IR)
according to the following equation:
Insulin resistance (HOMA-IR) = fasting blood insulin (mIU/
mL)6fasting blood glucose (mg/dL)/405.
Ultrasound Imaging of Carotid Intima–media Thickness
(CIMT)
As described previously [12], a high-resolution B-mode
ultrasound system (Vivid 7, General Electric, Horten, Norway)
with a 12-MHz transducer can be used to determine the
thicknesses of the bilateral carotid intima–media using semi-
Table 2. Basic characteristics according to tertile increment of adiponectin based on each genders.
men (n=454) 1st tertile #6.25 2nd tertile .6.25 3rd tertile .9.75 P value
Age, y 55.4966.73 57.1667.36 58.8967.03 ,.001
Waist circumference, cm 88.0867.24 87.8066.95 85.4267.35 0.002
Body mass index 24.8162.92 24.5864.24 24.8063.92 0.367
Smoking history, n (%) 0.108
current smoker 66 (43.42) 49 (32.23) 51 (33.55)
ex-smoker 48 (31.57) 48 (31.58) 41 (26.97)
non-smoker 38 (25.00) 55 (36.18) 58 (38.16)
SBP, mmHg 129.50617.38 127.99615.10 128.21615.06 0.919
DBP, mmHg 83.31611.86 83.01611.31 82.5369.75 0.826
FBG, mg/dL 98.92621.56 95.28617.29 91.51614.73 ,.001
FBI, mIU/mL 7.75 (6.20–9.65) 6.75 (5.57–8.57) 6.2 (5.23–8.00) ,.001
HOMA-IR 1.89 (1.43–2.45) 1.60 (1.29–2.04) 1.41 (1.14–1.73) ,.001
Total cholesterol, mg/dL 203.06634.98 198.67633.12 202.49638.58 0.507
Triglyceride, mg/dL 175.00 (117.00–240.75) 130.50 (95.00–190.25) 114.50 (82.00–172.50) ,.001
HDL-C, mg/dL 43.00 (37.00–50.25) 45.00 (39.00–52.25) 49.50 (42.00–58.00) ,.001
LDL-C, mg/dL 117.79631.72 115.63629.39 115.77632.08 0.795
CIMT, mm 0.91 (0.76–1.04) 0.84 (0.72–1.00) 0.84 (0.68–0.99) 0.022
% of high CIMT (.0.9 mm), n (%) 78 (51.31) 62 (40.79) 57 (37.50) 0.047*
women (n=579) 1st tertile #9.45 2nd tertile .9.45 3rd tertile .13.40
Age, y 53.9866.86 55.4467.54 56.7767.23 0.001
Waist circumference, cm 85.1568.18 83.0668.16 80.6168.96 ,.001
Body mass index 24.4968.88 24.4863.05 24.1764.28 0.115
Smoking history, n (%) 0.372
current smoker 8 (4.17) 7 (3.63) 5 (2.58)
ex-smoker 1 (0.52) 3 (1.55) 0 (0.00)
non-smoker 183 (95.31) 183 (94.82) 189 (97.42)
SBP, mmHg 130.17616.29 130.66615.61 129.27617.05 0.336
DBP, mmHg 82.50610.23 81.14610.74 80.96610.51 0.305
FBG, mg/dL 92.46620.44 92.68617.26 88.2469.31 0.002
FBI, mIU/mL 8.4 (6.77–11.12) 7.8 (6.5–10.2) 7.3 (5.9–8.9) ,.001
HOMA-IR 1.95 (1.46–2.58) 1.74 (1.39–2.39) 1.6 (1.23–1.97) ,.001
Total cholesterol, mg/dL 213.07643.57 214.33636.50 206.46640.23 0.075
Triglyceride, mg/dL 129 (95–203.25) 127 (91–168) 99 (74.25–137.75) ,.001
HDL-C, mg/dL 44.5 (38–50) 48 (42–57) 49 (43–59) ,.001
LDL-C, mg/dL 130.44638.37 128.55631.34 121.58631.35 0.027
CIMT, mm 0.88 (0.75–1) 0.84 (0.71–0.96) 0.8 (0.71–0.92) 0.018
% of high CIMT (.0.9 mm), n (%) 89 (46.35) 74 (38.34) 64 (32.99) 0.026*
SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose; FBI, fasting blood insulin;, HOMA-IR, Homeostasis model assessment-insulin
resistance; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; CIMT, carotid intima media thickness.
*p for trend.
doi:10.1371/journal.pone.0075535.t002
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automated edge-detection software. The minimum, maximum,
and mean values of CIMT were calculated from both sides. The
maximum CIMT levels from both sides were used as surrogates of
atherosclerosis [15].
Statistical Analysis
All statistical analyses were performed after stratifying for
gender. Data in this study are expressed as frequencies with
percent, means with standard deviation, or medians with inter-
quartile range. The probability of the risk of atherosclerosis was
plotted in relation to the adiponectin level. The odds ratios with
95% confidence intervals were calculated with respect to tertile
increments in adiponectin level for both genders. The indepen-
dence of the effects of adiponectin was estimated by multiple
logistic regression models, and the additional effect of adiponectin
was evaluated as the area under the receiver operating character-
istics (ROC) curve. Furthermore, We calculated the net reclassi-
fication improvement (NRI) and the integrated discrimination
improvement (IDI) to measure the quantifying improvement of
correct reclassification and sensitivity according to addition of
serum adiponectin in logistic regression model [16]. Values of p
(two-tailed) less than 0.05 were considered to be statistically
significant.
Results
Anthropometric and Metabolic Characteristics (Table 1)
Of the 1033 participants, 454 were men and 579 were women.
The values of waist circumference, diastolic blood pressure, FBG,
and triglycerides in men were higher than those in women. Body
mass index, FBI, HOMA-IR, total cholesterol, HDL-C, and LDL-
C levels were lower in men than in women.
Anthropometric and Metabolic Characteristics According
to Tertile Increment of Adiponectin (Table 2)
There was an inverse relationship between waist circumference
and tertile increment of adiponectin in men. The levels of FBG,
FBI, HOMA-IR and triglycerides decreased, whereas HDL-C
increased according to the tertile increment of adiponectin in both
genders. In addition, LDL-C levels showed an inverse relationship
with the tertile increment of adiponectin in women.
The median levels of CIMT and the percentage of high CIMT
decreased with the tertile increment of adiponectin in both
genders.
Logistic Regression Plot for Risk of High CIMT According
to Adiponectin Level (Figure 1)
The risk of a high CIMT decreased in inverse relation to
adiponectin levels in both genders. The dotted lines in figure 1
indicate the median level of adiponectin in each tertile level
(4.71 mg/L in 1st tertile, 7.85 mg/L in 2nd tertile, 12.52 mg/L in
Figure 1. Logistic regression plot for risk of subclinical atherosclerosis (carotid intima media thickness .0.9 mm) according to
adiponectin level. The dot lines indicate the median level of adiponectin in each tertile levels (4.71 in 1st tertile, 7.85 in 2nd tertile, 12.52 in 3rd tertile
in men; 7.36 in 1st tertile, 11.53 in 2nd tertile, 16.72 in 3rd tertile in women, unit =mg/L).
doi:10.1371/journal.pone.0075535.g001
Table 3. Odds ratio according to adiponectin of subclinical atherosclerosis (carotid intima media thickness .0.9).
Odds ratio (95% confidence interval)
Model I Model II Model III
Men ( = 454) Adiponectin (mg/L) 1st tertile #6.29 1 - 1 - 1 -
2nd tertile .6.29 0.57 (0.36–0.92) 0.55 (0.34–0.88) 0.50 (0.30–0.82)
3rd tertile .9.90 0.45 (0.28–0.74) 0.44 (0.27–0.73) 0.42 (0.25–0.72)
Women ( = 579) Adiponectin (mg/L) 1st group #9.45 1 - 1 - 1 -
2nd group .9.45 0.66 (0.43–0.99) 0.59 (0.38–0.91) 0.69 (0.44–1.06)
3rd group .13.40 0.48 (0.31–0.74) 0.38 (0.24–0.60) 0.47 (0.29–0.75)
Model I: adjusted for age.
Model II: model I+waist circumference and smoking history (and menopause status in women).
Model III: model II+low density lipoprotein cholesterol, high density lipoprotein cholesterol, triglyceride, systolic blood pressure and homeostasis model assessment-
insulin resistance.
doi:10.1371/journal.pone.0075535.t003
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3rd tertile in men; 7.36 mg/L in 1st tertile, 11.53 mg/L in 2nd
tertile, 16.72 mg/L in 3rd tertile in women). The density of the
circles indicates the number of samples counted in each range. In
each tertile of adiponectin, there were inverse relationships
between adiponectin and the risk of high CIMT for both genders.
Multiple Logistic Regression Models for Risk of High CIMT
According to Tertile Increment of Adiponectin (Table 3)
The adiponectin level had an inverse correlation with the risk of
high CIMT in both genders, independent of conventional
cardiovascular risk factors. When the adiponectin level of the
third tertile was compared to that of the first tertile, the OR
(95%CI) was 0.45 (0.28–0.74) in men and 0.48 (0.31–0.74) in
women, after adjustment for age. Waist circumference and
smoking history did not attenuate these associations in either
gender. After adjustment for conventional cardiovascular risk
factors, such as LDL-C, HDL-C, triglycerides, blood pressure, and
HOMA-IR, the OR (95%CI) of the third tertile was 0.42 (0.25–
0.72) in men and 0.47 (0.29–0.75) in women.
The Additional Contribution of Adiponectin to Predicting
Risk of High CIMT (Figure 2)
The AUC of the ROC analysis was 0.655 in men and 0.654 in
women, based on logistic regression models that included age,
waist circumference, smoking history, LDL-C, HDL-C, triglycer-
ides and HOMA-IR, and menopause history in women. The
significantly increased, by 0.025 in men and 0.022 in women,
when adiponectin was added to the models (AUC in men: 0.655 to
0.680, p = 0.038, AUC in women: 0.654 to 0.676, p = 0.041).
The category-free NRI was 0.32 (95%CI: 0.13–0.50, p,0.001),
and the IDI was 0.03 (95%CI: 0.01–0.04, p,0.001) for men. For
women, the category-free NRI was 0.18 (95%CI: 0.02–0.34,
p = 0.031) and the IDI was 0.003 (95%CI: 20.002–0.008,
p = 0.189). Hence, addition of adiponectin to the model reclassi-
fied 31% more cases in the correct direction in men and 18%
more cases in women, respectively.
Discussion
This community-based cross-sectional study demonstrated that:
1) there were significant relationships between adiponectin and
atherosclerosis in both genders; 2) these associations persisted after
adjustment for conventional cardiovascular risk factors in both
genders; and 3) adiponectin makes an additional contribution to
predicting the risk of atherosclerosis, beyond the information
provided by conventional cardiovascular risk factors.
Adiponectin is a kind of circulating adipokine that is associated
with endothelial dysfunction [17]. Adiponectin can become
attached to the endothelial walls of injured vessels [18] and can
control leukocyte–endothelium interactions by up-regulating the
expression of endothelial cell adhesion molecules [19]. In addition,
adiponectin reduces endothelial nitric oxide synthase (eNOS)
activity induced by oxidized low-density lipoprotein or hypergly-
cemic conditions [20,21]. These pathophysiologic actions of
adiponectin have led many authors to suggest that it may play a
protective role against atherosclerosis. Our current results support
such a protective effect of adiponectin in both genders.
Although there is now a large body of evidence for the
protective role of adiponectin against atherosclerosis in both
genders, some studies reported that adiponectin did not show an
independent association with atherosclerosis [9]. However, these
studies did not use gender-specific analyses, despite the fact that
levels of serum adiponectin differ greatly between men and women
[22]. These hormonal variations may affect the clinical features of
atherosclerosis according to gender. In general, serum adiponectin
levels are higher in women than those in men, because there is a
gender difference in the way it is synthesized and secreted. As with
other sex hormones, these gender differences begin at puberty
[23]. Specifically, testosterone is positively associated with
atherosclerotic risk factors, independently of aging and other risk
factors [24]. Furthermore, testosterone inhibits the high-molecu-
lar-weight active form of adiponectin [25]. Therefore, careful
consideration of the gender effect is a prerequisite in any study of
adiponectin and atherosclerosis. In the present study, the
adiponectin levels in women were so much higher than those in
men that both genders could not be included in a single logistic
regression model. Therefore, gender stratification analyses were
undertaken to elucidate the exact role of adiponectin in both
genders, while the conclusion that adiponectin provides additional
evidence for the assessment of atherosclerotic risk was drawn from
separate gender-stratified logistic regression models (table 3,
figure 2).
Figure 2. The additional contribution of adiponectin to predicting risk of high CIMT Model I include the age, waist circumference,
smoking history, low density lipoprotein cholesterol, high density lipoprotein cholesterol, triglyceride and homeostasis model
assessment-insulin resistance (and menopause history in women).
doi:10.1371/journal.pone.0075535.g002
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Adiponectin was inversely correlated with the risk of athero-
sclerosis, independently of the conventional cardiovascular risk
factors. When the adiponectin level in the third tertile was
compared to that in the first tertile, the ORs (95%CI) were 0.45
(0.28–0.74) in men and 0.48 (0.31–0.74) in women, after
adjustment for age. These associations persisted in both genders
after adjustment for conventional cardiovascular risk factors, such
as waist circumference, smoking history, LDL-C, HDL-C,
triglycerides, blood pressure, and HOMA-IR. Insulin resistance,
obesity, and lipid metabolism play an important pathogenetic role
in the development of cardiovascular diseases, including athero-
sclerosis [16,26]. In the present study, the association between
adiponectin and atherosclerosis was not attenuated when HOMA-
IR, waist circumference and lipid profiles were taken into account.
These results indicate that adiponectin has an adjunctive
pathophysiology, different from that of other conventional
cardiovascular risk factors.
The total sum of sensitivity and specificity of the various
biomarkers was represented by the ROC analysis [27], with a
higher AUC indicating a better model for explaining the target
outcome. In this study, we demonstrated that adding adiponectin
to conventional cardiovascular risk factors increased the AUC
(figure 2). The NRI could give clinical information by showing the
quantifying improvement by addition of new biomarkers to the
previous model. The IDI indicated the increased sensitivity by
addition of new biomarkers without sacrificing specificity. Hence,
the NRI and the IDI be more sensitive than the AUC in the ROC
analysis for indentifying improvements in predictive value [16]. In
the current study, addition of adiponectin increased the NRI in
both gender, and improved overall sensitivity measured by IDI in
men. These results indicate that adiponectin could provide
additional clinical information about the risk of atherosclerosis,
beyond that provided by conventional cardiovascular risk factors.
This study had some limitations. Because of its cross-sectional
nature, we were unable to determine a causal relationship between
atherosclerosis and adiponectin. In addition, we only examined
total adiponectin level rather than the high-molecular-weight and
active forms [28]. Therefore, further longitudinal studies using the
active form of adiponectin are needed.
In summary, the results of this study support the existence of a
significant relationship between adiponectin and atherosclerosis in
both genders, independent of conventional cardiovascular risk
factors. Furthermore, we demonstrated that adiponectin provides
additional information for the assessment of atherosclerotic risk,
beyond that provided by the conventional cardiovascular risk
factors.
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